原发性喉癌患者血清TXNIP、BIRC5水平在临床分期判断及疗效监测中的价值  

Value of serum TXNIP and BIRC5 levels in clinical staging and efficacy monitoring in patients with primary laryngeal cancer

作　　者：魏媛媛[1] 熊浪 周林[1] WEI Yuanyuan;XIONG Lang;ZHOU Lin(Department of Ear,Nose and Throat,Ezhou Central Hospital,Ezhou,Hubei 436000,China;Department of Surgical Anesthesiology,Ezhou Central Hospital,Ezhou,Hubei 436000,China)

机构地区：[1]鄂州市中心医院耳鼻喉科,湖北鄂州436000 [2]鄂州市中心医院手术麻醉科,湖北鄂州436000

出　　处：《国际检验医学杂志》2024年第10期1253-1256,1261,共5页International Journal of Laboratory Medicine

摘　　要：目的 探讨原发性喉癌(PLC)患者血清硫氧还蛋白结合蛋白(TXNIP),凋亡抑制因子5(BIRC5)水平在临床分期判断及疗效监测中的价值。方法 选取本院2020年6月至2023年1月期间收治的68例PLC患者为PLC组,将80例良性病变患者设为良性肿瘤组,患者治疗6个月后根据RECIST实体瘤疗效评价标准将PLC组患者分为治疗有效组(50例)和治疗无效组(18例)。采用酶联免疫吸附试验(ELISA)检测各组血清TXNIP、BIRC5水平;TXNIP、BIRC5对PLC分期诊断效能及PLC患者疗效预测效能采用受试者工作特征(ROC)曲线进行分析。结果 PLC组和良性肿瘤组患者血清TXNIP、BIRC5水平比较,差异有统计学意义(P<0.05)。治疗有效组血清TXNIP水平[(99.52±14.12)pg/mL]显著高于治疗无效组[(85.19±15.17)pg/mL],差异有统计学意义(t=3.621,P<0.05),BIRC5水平[(15.26±3.65)pg/mL]显著低于治疗无效组[(19.13±3.74)pg/mL],差异有统计学意义(t=3.833,P<0.05)。早期PLC患者血清TXNIP水平[(101.39±12.85)pg/mL]显著高于晚期患者[(91.27±13.36)pg/mL],差异有统计学意义(t=3.154,P<0.05),BIRC5水平[(14.43±3.07)pg/mL]显著低于晚期患者(17.74±3.04),差异有统计学意义(t=4.439,P<0.05)。血清TXNIP、BIRC5诊断PLC分期的线下面积(AUC)分别为0.829(95%CI:0.718~0.909)、0.795(95%CI:0.679~0.883),灵敏度分别为81.58%、89.47%,且TXNIP、BIRC5联合诊断PLC分期的AUC为0.899(95%CI:0.802~0.959),灵敏度为94.74%;血清TXNIP、BIRC5预测PLC患者疗效的AUC分别为0.818(95%CI:0.705~0.901)、0.761(95%CI:0.642~0.856),二者联合AUC为0.921(95%CI:0.830~0.973),具有更高的预测效能(P<0.05)。结论 TXNIP在PLC患者血清中呈低表达,BIRC5PLC患者血清中呈高表达,TXNIP和BIRC5二者联合检测对PLC分期的诊断和PLC患者疗效的预测具有一定效能。Objective To explore the value of expression levels of serum thioredoxin-interacting protein(TXNIP)and baculoviral IAP repeat-containing protein 5(BIRC5)in clinical staging and efficacy monitoring in patients with primary laryngeal cancer(PLC).Methods From June 2020 to January 2023,a total of 68 patients with PLC accepted by the hospital were collected as PLC group,and 80 patients with benign lesions were set as the benign tumors group.After six months of treatment,patients in the PLC group were separated into the treatment effective group(50 cases)and the treatment ineffective group(18 cases)according to the RECIST solid tumor efficacy evaluation criteria.Enzyme linked immunosorbent assay(ELISA)was applied to detect the levels of TXNIP and BIRC5 in serum of each group;the diagnostic efficacy of TXNIP and BIRC5 in staging PLC and the predictive efficacy of PLC patients were analyzed using the receiver operating characteristic(ROC)curve.Results There were statistically significant differences in the expression levels of TXNIP and BIRC5 in the serum between the PLC group and the benign tumors group(P<0.05).The level of serum TXNIP in the treatment effective group[(99.52±14.12)pg/mL]was obviously higher than that in the treatment ineffective group[(85.19±15.17)pg/mL],and the difference was statistically significant(t=3.621,P<0.05),while the BIRC5 expression level[(15.26±3.65)pg/mL]was obviously lower than that in the treatment ineffective group[(19.13±3.74)pg/mL],and the difference was statistically significant(t=3.833,P<0.05).The serum TXNIP expression level in early PLC patients[(101.39±12.85)pg/mL]was obviously higher than that in late stage patients[(91.27±13.36)pg/mL],and the difference was statistically significant(t=3.154,P<0.05),while the BIRC5 expression level[(14.43±3.07)pg/mL]was obviously lower than that in late stage patients[(17.74±3.04)pg/mL],and the difference was statistically significant(t=4.439,P<0.05).The area under the curve(AUC)of serum TXNIP and BIRC5 in diagnosing PLC staging was 0.82

关 键 词：原发性喉癌 硫氧还蛋白结合蛋白 凋亡抑制因子5 临床分期 疗效预测 

分 类 号：R739.65[医药卫生—肿瘤]